These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 12899642)

  • 21. INGN 201: Ad-p53, Ad5CMV-p53, Adenoviral p53, INGN 101, p53 gene therapy--Introgen, RPR/INGN 201.
    BioDrugs; 2003; 17(3):216-22. PubMed ID: 12749760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of suicide genes for cancer gene therapy: study of the different approaches.
    Vassaux G; Martin-Duque P
    Expert Opin Biol Ther; 2004 Apr; 4(4):519-30. PubMed ID: 15102601
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Replicating viruses as selective cancer therapeutics.
    Kirn DH; McCormick F
    Mol Med Today; 1996 Dec; 2(12):519-27. PubMed ID: 9015793
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Herpes simplex virus-based vectors.
    Lachmann R
    Int J Exp Pathol; 2004 Oct; 85(4):177-90. PubMed ID: 15312123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of E1a modifications on tumor-selective adenoviral replication and toxicity.
    Sauthoff H; Pipiya T; Heitner S; Chen S; Bleck B; Reibman J; Chang W; Norman RG; Rom WN; Hay JG
    Mol Ther; 2004 Oct; 10(4):749-57. PubMed ID: 15451459
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of the biodistribution, persistence, toxicity, and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse.
    Paielli DL; Wing MS; Rogulski KR; Gilbert JD; Kolozsvary A; Kim JH; Hughes J; Schnell M; Thompson T; Freytag SO
    Mol Ther; 2000 Mar; 1(3):263-74. PubMed ID: 10933942
    [TBL] [Abstract][Full Text] [Related]  

  • 27. E1A- and E1B-Double mutant replicating adenovirus elicits enhanced oncolytic and antitumor effects.
    Kim J; Kim JH; Choi KJ; Kim PH; Yun CO
    Hum Gene Ther; 2007 Sep; 18(9):773-86. PubMed ID: 17725410
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Deletion of the adenoviral E1b-19kD gene enhances tumor cell killing of a replicating adenoviral vector.
    Sauthoff H; Heitner S; Rom WN; Hay JG
    Hum Gene Ther; 2000 Feb; 11(3):379-88. PubMed ID: 10697113
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor reduction in vivo after adenoviral mediated gene transfer of the herpes simplex virus thymidine kinase gene and ganciclovir treatment in human head and neck squamous cell carcinoma.
    Goebel EA; Davidson BL; Graham SM; Kern JA
    Otolaryngol Head Neck Surg; 1998 Oct; 119(4):331-6. PubMed ID: 9781985
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Distribution, persistency, toxicity, and lack of replication of an E1A-deficient adenoviral vector after intracardiac delivery in the cotton rat.
    Rojas-Martinez A; Wyde PR; Montgomery CA; Chen SH; Woo SL; Aguilar-Cordova E
    Cancer Gene Ther; 1998; 5(6):365-70. PubMed ID: 9917091
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oncolytic herpes simplex virus vectors for cancer virotherapy.
    Varghese S; Rabkin SD
    Cancer Gene Ther; 2002 Dec; 9(12):967-78. PubMed ID: 12522436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vaccinia virus and oncolytic virotherapy of cancer.
    Thorne SH; Hwang TH; Kirn DH
    Curr Opin Mol Ther; 2005 Aug; 7(4):359-65. PubMed ID: 16121702
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Herpes virus-based vectors.
    Efstathiou S; Minson AC
    Br Med Bull; 1995 Jan; 51(1):45-55. PubMed ID: 7767648
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Phase I study of replication-competent adenovirus-mediated double-suicide gene therapy in combination with conventional-dose three-dimensional conformal radiation therapy for the treatment of newly diagnosed, intermediate- to high-risk prostate cancer.
    Freytag SO; Stricker H; Pegg J; Paielli D; Pradhan DG; Peabody J; DePeralta-Venturina M; Xia X; Brown S; Lu M; Kim JH
    Cancer Res; 2003 Nov; 63(21):7497-506. PubMed ID: 14612551
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modified adenoviruses for cancer gene therapy.
    Kanerva A; Hemminki A
    Int J Cancer; 2004 Jul; 110(4):475-80. PubMed ID: 15122578
    [TBL] [Abstract][Full Text] [Related]  

  • 36. AdEasy-based cloning system to generate tropism expanded replicating adenoviruses expressing transgenes late in the viral life cycle.
    Lie-A-Ling M; Bakker CT; Wesseling JG; Bosma PJ
    Gene Ther; 2005 Sep; 12(17):1347-52. PubMed ID: 15877046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes.
    McCart JA; Ward JM; Lee J; Hu Y; Alexander HR; Libutti SK; Moss B; Bartlett DL
    Cancer Res; 2001 Dec; 61(24):8751-7. PubMed ID: 11751395
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of an E1E4-deleted adenovirus expressing the herpes simplex thymidine kinase suicide gene in cancer gene therapy.
    Lanuti M; Gao GP; Force SD; Chang MY; El Kouri C; Amin KM; Hughes JV; Wilson JM; Kaiser LR; Albelda SM
    Hum Gene Ther; 1999 Feb; 10(3):463-75. PubMed ID: 10048398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Replication-selective oncolytic viruses in the treatment of cancer.
    Everts B; van der Poel HG
    Cancer Gene Ther; 2005 Feb; 12(2):141-61. PubMed ID: 15472714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Viral delivery for gene therapy against cell movement in cancer.
    Wu TL; Zhou D
    Adv Drug Deliv Rev; 2011 Jul; 63(8):671-7. PubMed ID: 21616108
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.